Key result
Beta-blockers linked to ~33% lower 1-year mortality in Takotsubo syndrome.
Why the study?
There are limited clinical data for beta-blockers in Takotsubo syndrome regarding their impact on all-cause mortality.
Does post-diagnosis beta-blocker use reduce all-cause mortality in patients with Takotsubo syndrome?
Cohort (n=54,855)
Yes
Does post-diagnosis beta-blocker use reduce all-cause mortality in patients with Takotsubo syndrome?
Relative Risk: 0.67 (95% CI 0.63–0.71)
In a large real-world cohort, post-diagnosis beta-blocker use in patients with Takotsubo syndrome was associated with significantly reduced all-cause mortality at 1, 3, and 5 years.
May support beta-blocker consideration in TTS; leaves open causal confirmation in randomized trials.
AIMS: There are limited clinical data for beta-blockers in Takotsubo syndrome (TTS). This real-world analysis aims to evaluate the impact of beta-blockers on all-cause mortality in TTS. METHODS AND RESULTS: This retrospective analysis was conducted using the Global Collaborative Network of the TriNetX database. Patients with TTS were identified between 1 January 2005 and 6 June 2025 and stratified based on post-diagnosis beta-blocker use. Propensity-score matching using the greedy nearest-neighbour matching was utilized to balance the cohorts. The outcome of interest was in-hospital mortality at 1, 3, and 5 years. During the study period, 54 855 patients with TTS were identified (beta-blocker group: 39 108; control: 15 747). The beta-blocker group was on average older (71 vs. 69.7 years), of white race (74.2% vs. 68.9%), and had higher rates of comorbidities. Following matching, both cohorts had 14 268 patients each with a mean age of 70 years and were well balanced in demographics, comorbidities, medications, and laboratory data. Matched cohort analysis demonstrated that beta-blocker use was associated with lower all-cause mortality at 1 year [risk ratio (RR): 0.67; 95% confidence interval (CI): 0.63-0.71], 3 years (RR: 0.78; 95% CI: 0.74-0.82), and 5 years (RR: 0.81; 95% CI: 0.76-0.84). CONCLUSION: Beta-blocker use in patients with TTS was associated with a lower risk of short- and long-term mortality up to 5 years.
No takes yet. Share an insight, caveat, or question.
Jain et al. (2025) conducted a cohort in Takotsubo syndrome (n=54,855). Beta-blockers vs. Control (no beta-blocker) was evaluated on All-cause mortality at 1 year (RR 0.67, 95% CI 0.63-0.71). Beta-blocker use in patients with Takotsubo syndrome was associated with lower all-cause mortality at 1 year (RR 0.67; 95% CI 0.63-0.71), 3 years, and 5 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: